Related references
Note: Only part of the references are listed.The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease
Noemie Cresto et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2019)
Motor Complications in Parkinson's Disease: Striatal Molecular and Electrophysiological Mechanisms of Dyskinesias
Barbara Picconi et al.
MOVEMENT DISORDERS (2018)
Alpha-synuclein delays mitophagy and targeting Miro rescues neuron loss in Parkinson's models
Atossa Shaltouki et al.
ACTA NEUROPATHOLOGICA (2018)
Overexpression of TFEB Drives a Pleiotropic Neurotrophic Effect and Prevents Parkinson's Disease-Related Neurodegeneration
Albert Torra et al.
MOLECULAR THERAPY (2018)
Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic
S. Pablo Sardi et al.
MOVEMENT DISORDERS (2018)
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Anthony E. Lang et al.
MOVEMENT DISORDERS (2018)
GBA1 deficiency negatively affects physiological alpha-synuclein tetramers and related multimers
Sangjune Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Near-infrared deep brain stimulation via upconversion nanoparticle-mediated optogenetics
Shuo Chen et al.
SCIENCE (2018)
Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-a-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease A Randomized Clinical Trial
Joseph Jankovic et al.
JAMA NEUROLOGY (2018)
LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons
Michael X. Henderson et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
β2-adrenoreceptor medications and risk of Parkinson disease
Susan Searles Nielsen et al.
ANNALS OF NEUROLOGY (2018)
LRRK2 activation in idiopathic Parkinson's disease
Roberto Di Maio et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
143rd Annual Meeting American Neurological Association
ANNALS OF NEUROLOGY (2018)
Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils
Ying Fan et al.
BIOCHEMICAL JOURNAL (2018)
Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease
Andrew B. West
EXPERIMENTAL NEUROLOGY (2017)
Implantation of autologous peripheral nerve grafts into the substantia nigra of subjects with idiopathic Parkinson's disease treated with bilateral STN DBS: a report of safety and feasibility
Craig G. van Horne et al.
JOURNAL OF NEUROSURGERY (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Statins May Facilitate Parkinson's Disease: Insight Gained From a Large, National Claims Database
Guodong Liu et al.
MOVEMENT DISORDERS (2017)
Targeting -Synuclein as a therapy for Parkinson's disease: The battle begins
C. Warren Olanow et al.
MOVEMENT DISORDERS (2017)
Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model
Tetsuhiro Kikuchi et al.
NATURE (2017)
α-synuclein toxicity in neurodegeneration: mechanism and therapeutic strategies
Yvette C. Wong et al.
NATURE MEDICINE (2017)
Selective neuronal vulnerability in Parkinson disease
D. James Surmeier et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Non-motor features of Parkinson disease
Anthony H. V. Schapira et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease
Fabrizio Stocchi et al.
NEUROLOGY (2017)
The Retromer Supports AMPA Receptor Trafficking During LTP
Paul Temkin et al.
NEURON (2017)
A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein
Franziska Richter et al.
NEUROTHERAPEUTICS (2017)
Glucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
S. Pablo Sardi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
A natural product inhibits the initiation of α-synuclein aggregation and suppresses its toxicity
Michele Perni et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease
Shuchi Mittal et al.
SCIENCE (2017)
Phase IIb Study of Intranasal Glutathione in Parkinson's Disease
Laurie K. Mischley et al.
JOURNAL OF PARKINSONS DISEASE (2017)
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson's disease
Antonio Martin-Bastida et al.
SCIENTIFIC REPORTS (2017)
Mitochondrial division inhibitor-1 is neuroprotective in the A53T-α-synuclein rat model of Parkinson's disease
Simone Bido et al.
SCIENTIFIC REPORTS (2017)
Myeloperoxidase-immunoreactive cells are significantly increased in brain areas affected by neurodegeneration in Parkinson's and Alzheimer's disease
Sandra Gellhaar et al.
CELL AND TISSUE RESEARCH (2017)
α-Synuclein binds to the ER-mitochondria tethering protein VAPB to disrupt Ca2+ homeostasis and mitochondrial ATP production
Sebastien Paillusson et al.
ACTA NEUROPATHOLOGICA (2017)
Noninvasive Deep Brain Stimulation via Temporally Interfering Electric Fields
Nir Grossman et al.
CELL (2017)
Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease
Martin Niethammer et al.
JCI INSIGHT (2017)
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson's disease trial
Howard E. Gendelman et al.
NPJ PARKINSONS DISEASE (2017)
Active immunization therapies for Parkinson's disease and multiple system atrophy
Achim Schneeberger et al.
MOVEMENT DISORDERS (2016)
Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes
Wenzhang Wang et al.
NATURE MEDICINE (2016)
Physiology of freezing of gait
Anke H. Snijders et al.
ANNALS OF NEUROLOGY (2016)
Statin Therapy Prevents the Onset of Parkinson Disease in Patients with Diabetes
Kun-Der Lin et al.
ANNALS OF NEUROLOGY (2016)
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda et al.
DRUG DISCOVERY TODAY (2016)
A critical role for alpha-synuclein in development and function of T lymphocytes
Afshin Shameli et al.
IMMUNOBIOLOGY (2016)
Parkinson's disease: acid-glucocerebrosidase activity and alpha-synuclein clearance
Judith Blanz et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial
Emily J. Henderson et al.
LANCET NEUROLOGY (2016)
Neuroprotective Effect of the Marine-Derived Compound 11-Dehydrosinulariolide through DJ-1-Related Pathway in In Vitro and In Vivo Models of Parkinson's Disease
Chien-Wei Feng et al.
MARINE DRUGS (2016)
Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation
Milena Pinto et al.
MOLECULAR NEURODEGENERATION (2016)
Neuroprotective Effects of a Standardized Flavonoid Extract from Safflower against a Rotenone-Induced Rat Model of Parkinson's Disease
Nuramatjan Ablat et al.
MOLECULES (2016)
A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease
Francois Tison et al.
MOVEMENT DISORDERS (2016)
Non-motor symptoms in Parkinson's disease
Ronald F. Pfeiffer
PARKINSONISM & RELATED DISORDERS (2016)
Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3
Xiaobo Mao et al.
SCIENCE (2016)
Nilotinib Effects in Parkinson's Disease and Dementia with Lewy Bodies
Fernando Pagan et al.
JOURNAL OF PARKINSONS DISEASE (2016)
Deep Brain Stimulation: A Paradigm Shifting Approach to Treat Parkinson's Disease
Patrick Hickey et al.
FRONTIERS IN NEUROSCIENCE (2016)
Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action
Tay Kay Yaw et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2016)
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial
C. Warren Olanow et al.
ANNALS OF NEUROLOGY (2015)
Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease
Aurelija Jucaite et al.
BRAIN (2015)
Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons
Consiglia Pacelli et al.
CURRENT BIOLOGY (2015)
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
Benjamin Dehay et al.
LANCET NEUROLOGY (2015)
NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. (vol 14, pg 795, 2015)
Chadwick W. Christine
LANCET NEUROLOGY (2015)
Beta Oscillations in Freely Moving Parkinson's Subjects Are Attenuated During Deep Brain Stimulation
Emma J. Quinn et al.
MOVEMENT DISORDERS (2015)
Cell-based therapies for Parkinson disease-past insights and future potential
Roger A. Barker et al.
NATURE REVIEWS NEUROLOGY (2015)
Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration
Katrina L. Paumier et al.
NEUROBIOLOGY OF DISEASE (2015)
The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson's Disease
Alicia M. Pickrell et al.
NEURON (2015)
Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
Reina N. Fuji et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease Two Randomized Clinical Trials and Lessons Learned
Robert A. Hauser et al.
JAMA NEUROLOGY (2015)
GBA-Associated Parkinson's Disease: Reduced Survival and More Rapid Progression in a Prospective Longitudinal Study
Kathrin Brockmann et al.
MOVEMENT DISORDERS (2015)
PPARγ and PGC-1α as Therapeutic Targets in Parkinson's
Juan Carlos Corona et al.
NEUROCHEMICAL RESEARCH (2015)
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Tanya Simuni et al.
LANCET NEUROLOGY (2015)
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials
Markus Mandler et al.
ACTA NEUROPATHOLOGICA (2014)
Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys
Ariadna Recasens et al.
ANNALS OF NEUROLOGY (2014)
Mitochondrial Energy Metabolism and Redox Signaling in Brain Aging and Neurodegeneration
Fei Yin et al.
ANTIOXIDANTS & REDOX SIGNALING (2014)
Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes
Huajun Jin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2014)
Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells
Alisdair McNeill et al.
BRAIN (2014)
Human ESC-Derived Dopamine Neurons Show Similar Preclinical Efficacy and Potency to Fetal Neurons when Grafted in a Rat Model of Parkinson's Disease
Shane Grealish et al.
CELL STEM CELL (2014)
LRRK2, a puzzling protein: Insights into Parkinson's disease pathogenesis
A. Raquel Esteves et al.
EXPERIMENTAL NEUROLOGY (2014)
Pharmacological Treatment of Parkinson Disease A Review
Barbara S. Connolly et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
LRRK2 pathobiology in Parkinson's disease
Ian Martin et al.
JOURNAL OF NEUROCHEMISTRY (2014)
alpha-Synuclein Is Localized to Mitochondria-Associated ER Membranes
Cristina Guardia-Laguarta et al.
JOURNAL OF NEUROSCIENCE (2014)
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial
Stephane Palfi et al.
LANCET (2014)
The role of iron in brain ageing and neurodegenerative disorders
Roberta Ward et al.
LANCET NEUROLOGY (2014)
Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease
Mike A. Nalls et al.
NATURE GENETICS (2014)
Mitochondrial oxidant stress in locus coeruleus is regulated by activity and nitric oxide synthase
Javier Sanchez-Padilla et al.
NATURE NEUROSCIENCE (2014)
The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse
Mari H. Savolainen et al.
NEUROBIOLOGY OF DISEASE (2014)
Deep-Brain Stimulation - Entering the Era of Human Neural-Network Modulation
Michael S. Okun
NEW ENGLAND JOURNAL OF MEDICINE (2014)
AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces L-Dopa-induced dyskinesias and extends the duration of L-Dopa effects in parkinsonian monkeys
Therese Di Paolo et al.
PARKINSONISM & RELATED DISORDERS (2014)
Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy
Eszter Zavodszky et al.
NATURE COMMUNICATIONS (2014)
Inosine to Increase Serum and Cerebrospinal Fluid Urate in Parkinson Disease A Randomized Clinical Trial
Michael A. Schwarzschild et al.
JAMA NEUROLOGY (2014)
LAMP2A as a therapeutic target in Parkinson disease
Maria Xilouri et al.
AUTOPHAGY (2013)
Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase
Inna Bendikov-Bar et al.
BLOOD CELLS MOLECULES AND DISEASES (2013)
Nigral stimulation for resistant axial motor impairment in Parkinson's disease? A randomized controlled trial
Daniel Weiss et al.
BRAIN (2013)
Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease
Heather Mortiboys et al.
BRAIN (2013)
The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering
Denis Ottolini et al.
HUMAN MOLECULAR GENETICS (2013)
Calcium, Bioenergetics, and Neuronal Vulnerability in Parkinson's Disease
D. James Surmeier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Parkinson's disease subtypes: lost in translation?
Connie Marras et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2013)
Gait Disorders in Parkinsonian Monkeys with Pedunculopontine Nucleus Lesions: A Tale of Two Systems
David Grabli et al.
JOURNAL OF NEUROSCIENCE (2013)
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease
Roger A. Barker et al.
LANCET NEUROLOGY (2013)
Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients
Raymond T. Bartus et al.
NEUROLOGY (2013)
Leucine-Rich Repeat Kinase 2 (LRRK2)-Deficient Rats Exhibit Renal Tubule Injury and Perturbations in Metabolic and Immunological Homeostasis
Daniel Ness et al.
PLOS ONE (2013)
Parkin Disease A Clinicopathologic Entity?
Karen M. Doherty et al.
JAMA NEUROLOGY (2013)
A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease
T. T. Myohanen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Gabriele Mittermeyer et al.
HUMAN GENE THERAPY (2012)
Neuroprotection by urate on 6-OHDA-lesioned rat model of Parkinson's disease: linking to Akt/GSK3β signaling pathway
Li Gong et al.
JOURNAL OF NEUROCHEMISTRY (2012)
Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission
Eun-Jin Bae et al.
JOURNAL OF NEUROSCIENCE (2012)
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial (vol 11, pg 589, 2012)
C. Moreau et al.
LANCET NEUROLOGY (2012)
The neuropathology of genetic Parkinson's disease
Markos Poulopoulos et al.
MOVEMENT DISORDERS (2012)
Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson's disease
Joshua A. Goldberg et al.
NATURE NEUROSCIENCE (2012)
Viral vectors for gene delivery to the central nervous system
Thomas B. Lentz et al.
NEUROBIOLOGY OF DISEASE (2012)
Inflammation and Adaptive Immunity in Parkinson's Disease
R. Lee Mosley et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)
Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial
Caroline Moreau et al.
LANCET NEUROLOGY (2012)
Pallidal Dysfunction Drives a Cerebellothalamic Circuit into Parkinson Tremor
Rick C. Helmich et al.
ANNALS OF NEUROLOGY (2011)
The Interplay Between Mitochondrial Dynamics and Mitophagy
Gilad Twig et al.
ANTIOXIDANTS & REDOX SIGNALING (2011)
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Joo-Ho Shin et al.
CELL (2011)
Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in Synucleinopathies
Joseph R. Mazzulli et al.
CELL (2011)
LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice
Martin C. Herzig et al.
HUMAN MOLECULAR GENETICS (2011)
Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration
David T. Dexter et al.
JOURNAL OF NEURAL TRANSMISSION (2011)
AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial
Peter A. LeWitt et al.
LANCET NEUROLOGY (2011)
Aggregation of α-synuclein in brain samples from subjects with glucocerebrosidase mutations
Jae Hyuk Choi et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease
Sonja Kriks et al.
NATURE (2011)
Incidental Lewy body disease: Do some cases represent a preclinical stage of dementia with Lewy bodies?
Roberta Frigerio et al.
NEUROBIOLOGY OF AGING (2011)
Use of ibuprofen and risk of Parkinson disease
Xiang Gao et al.
NEUROLOGY (2011)
Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death
Laura A. Volpicelli-Daley et al.
NEURON (2011)
Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease
Eliezer Masliah et al.
PLOS ONE (2011)
Current Use of Clozapine in Parkinson Disease and Related Disorders
Alissa A. Thomas et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Preladenant, a selective A2A receptor antagonist, is active in primate models of movement disorders
Robert A. Hodgson et al.
EXPERIMENTAL NEUROLOGY (2010)
Rapamycin Protects against Neuron Death in In Vitro and In Vivo Models of Parkinson's Disease
Cristina Malagelada et al.
JOURNAL OF NEUROSCIENCE (2010)
Pathogenic Lysosomal Depletion in Parkinson's Disease
Benjamin Dehay et al.
JOURNAL OF NEUROSCIENCE (2010)
Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial
Adrian Williams et al.
LANCET NEUROLOGY (2010)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
A Phase I Study of Aromatic L-Amino Acid Decarboxylase Gene Therapy for Parkinson's Disease
Shin-ichi Muramatsu et al.
MOLECULAR THERAPY (2010)
The Identification of Parkinson's Disease Subtypes Using Cluster Analysis: A Systematic Review
Stephanie M. van Rooden et al.
MOVEMENT DISORDERS (2010)
Role of Serotonin Neurons in the Induction of Levodopa- and Graft-Induced Dyskinesias in Parkinson's Disease
Manolo Carta et al.
MOVEMENT DISORDERS (2010)
A Double-Blind, Placebo-Controlled Study to Assess the Mitochondria-Targeted Antioxidant MitoQ as a Disease-Modifying Therapy in Parkinson's Disease
Barry J. Snow et al.
MOVEMENT DISORDERS (2010)
Enhancement of proteasome activity by a small-molecule inhibitor of USP14
Byung-Hoon Lee et al.
NATURE (2010)
Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1
Jaime N. Guzman et al.
NATURE (2010)
Anti-inflammatory drugs and risk of Parkinson disease A meta-analysis
Joshua J. Gagne et al.
NEUROLOGY (2010)
Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease
Kathryn A. Chung et al.
NEUROLOGY (2010)
Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo
Shankar J. Chinta et al.
NEUROSCIENCE LETTERS (2010)
Pallidal versus Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Kenneth A. Follett et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial
H. H. Fernandez et al.
PARKINSONISM & RELATED DISORDERS (2010)
Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?
K. L. Double et al.
PROGRESS IN NEUROBIOLOGY (2010)
Cognition and Mood in Parkinson's Disease in Subthalamic Nucleus versus Globus Pallidus Interna Deep Brain Stimulation: The COMPARE Trial
Michael S. Okun et al.
ANNALS OF NEUROLOGY (2009)
Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and Stability
Raquel L. Lieberman et al.
BIOCHEMISTRY (2009)
Effects of nigral stimulation on locomotion and postural stability in patients with Parkinsons disease
N. Chastan et al.
BRAIN (2009)
NSAID Use and the Risk of Parkinson's Disease Systematic Review and Meta-Analysis of Observational Studies
Ali Samii et al.
DRUGS & AGING (2009)
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients With Advanced Parkinson Disease A Randomized Controlled Trial
Frances M. Weaver et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Beclin 1 Gene Transfer Activates Autophagy and Ameliorates the Neurodegenerative Pathology in α-Synuclein Models of Parkinson's and Lewy Body Diseases
Brian Spencer et al.
JOURNAL OF NEUROSCIENCE (2009)
Neuroinflammation in Parkinson's disease: a target for neuroprotection?
Etienne C. Hirsch et al.
LANCET NEUROLOGY (2009)
Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease
Wataru Satake et al.
NATURE GENETICS (2009)
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Javier Simon-Sanchez et al.
NATURE GENETICS (2009)
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss
Luke S. Tain et al.
NATURE NEUROSCIENCE (2009)
Safety and tolerability of putaminal AADC gene therapy for Parkinson disease
C. W. Christine et al.
NEUROLOGY (2009)
Multicenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
E. Sidransky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces Off' time in Parkinson's disease:: A double-blind, randomized, multicenter clinical trial (6002-US-005)
Peter A. LeWitt et al.
ANNALS OF NEUROLOGY (2008)
Glucagon-like peptide I receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
Alexander Harkavyi et al.
JOURNAL OF NEUROINFLAMMATION (2008)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
Daniel G. Healy et al.
LANCET NEUROLOGY (2008)
Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctuations
Robert A. Hauser et al.
MOVEMENT DISORDERS (2008)
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
Jeffrey H. Kordower et al.
NATURE MEDICINE (2008)
Results from a phase I safety trial of hAADC gene therapy for Parkinson disease
J. L. Eberling et al.
NEUROLOGY (2008)
Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease
Angelika D. Wahner et al.
NEUROLOGY (2007)
Plasma urate and risk of Parkinson's disease
M. G. Weisskopf et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2007)
Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo
Pivi Lindholm et al.
NATURE (2007)
AAV2 - mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tolerability of CERE-120 for Parkinson's disease
Mehdi Gasmi et al.
NEUROBIOLOGY OF DISEASE (2007)
Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial
Michael G. Kaplitt et al.
LANCET (2007)
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys
Christopher D. Herzog et al.
MOVEMENT DISORDERS (2007)
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease
Alessandro Stefani et al.
BRAIN (2007)
Individual dopaminergic neurons show raised iron levels in Parkinson disease
A. E. Oakley et al.
NEUROLOGY (2007)
Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism
Marina E. Emborg et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2007)
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2006)
Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes
Neeta S. Roy et al.
NATURE MEDICINE (2006)
A randomized trial of deep-brain stimulation for Parkinson's disease
Guenther Deuschl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors
Kazutoshi Takahashi et al.
CELL (2006)
Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease
Thanh G. Ton et al.
MOVEMENT DISORDERS (2006)
2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin
Ira E. Clark et al.
NATURE (2006)
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Jeehye Park et al.
NATURE (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Non-motor symptoms of Parkinson's disease: diagnosis and management
KR Chaudhuri et al.
LANCET NEUROLOGY (2006)
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
A Gerhard et al.
NEUROBIOLOGY OF DISEASE (2006)
Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease
P Plaha et al.
NEUROREPORT (2005)
Serum uric acid levels and the risk of Parkinson disease
LML de Lau et al.
ANNALS OF NEUROLOGY (2005)
Effects of α-synuclein immunization in a mouse model of Parkinson's disease
E Masliah et al.
NEURON (2005)
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor
JT Slevin et al.
JOURNAL OF NEUROSURGERY (2005)
Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study
NK Patel et al.
ANNALS OF NEUROLOGY (2005)
Microglial activation and dopamine terminal loss in early Parkinson's disease
Y Ouchi et al.
ANNALS OF NEUROLOGY (2005)
Neuroprotective effects of vascular endothelial growth factor (VEGF) upon dopaminergic neurons in a rat model of Parkinson's disease
T Yasuhara et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2004)
Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy
AM Cuervo et al.
SCIENCE (2004)
Pedunculopontine nucleus stimulation improves akinesia in a Parkinsonian monkey
N Jenkinson et al.
NEUROREPORT (2004)
Neuroimmunophilins: A novel drug therapy for the reversal of neurodegenerative disease?
MO Poulter et al.
NEUROSCIENCE (2004)
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
CW Olanow et al.
ANNALS OF NEUROLOGY (2003)
α-synuclein is degraded by both autophagy and the proteasome
JL Webb et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism?
N Tayebi et al.
MOLECULAR GENETICS AND METABOLISM (2003)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Staging of brain pathology related to sporadic Parkinson's disease
H Braak et al.
NEUROBIOLOGY OF AGING (2003)
Tremor in Parkinson's disease and serotonergic dysfunction -: An 11C-WAY 100635 PET study
M Doder et al.
NEUROLOGY (2003)
Dyskinesia after fetal cell transplantation for parkinsonism: A PET study
YL Ma et al.
ANNALS OF NEUROLOGY (2002)
Effects of coenzyme Q10 in early Parkinson disease -: Evidence of slowing of the functional decline
CW Shults et al.
ARCHIVES OF NEUROLOGY (2002)
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
F Bibbiani et al.
NEUROLOGY (2001)
Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats
R Sánchez-Pernaute et al.
MOLECULAR THERAPY (2001)
Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature
JE Ahlskog et al.
MOVEMENT DISORDERS (2001)
Transplantation of embryonic dopamine neurons for severe Parkinson's disease.
CR Freed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
